Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia

Kang, Chuan Yuan; Xu, Xiu Feng; Liu, Hua; Shi, Zhiyu; Hong, Xu; Jian, Yang

doi:10.1016/j.psychres.2009.02.009

Cited by 14 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 36 These findings are consistent with the studies using next-generation sequencing which reported associations with the Met allele and severe psychopathology, poor response, resistance to conventional APs, and the need to use higher doses of drugs in resistant patients. 25 , 37 , 38 On the other hand, Molero et al 39 reported an association between Val/Val and a poor response; meanwhile, Kang et al 40 and a recent meta-analysis carried out by Hwang et al 20 reported an association between response and the Met/Met genotype. There is also a series of studies that did not find any association between Val158Met and the response to treatment.…”

Section: Discussionmentioning

confidence: 99%

Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

Escamilla¹,

Camarena²,

Saracco-Álvarez³

et al. 2018

NDT

View full text Add to dashboard Cite

PurposeThe efficacy of schizophrenia treatments using antipsychotics (APs) has long been established, but the benefit obtained by several patients using conventional APs (typical or atypical) has not been enough. Currently, the genetic study of the primary mechanisms of action of the APs has been focused on the dopaminergic pathways. The objective of this study was to determine if the response phenotypes (responder, resistance to treatment, and ultra-resistance to treatment groups) are associated with six single-nucleotide polymorphisms: COMT (Val158Met), DRD2 (A-241G, C376G, C939T, Taq1A), and DRD3 (Ser9Gly).Patients and methodsWe classified the patients through a retrospective/prospective methodology to define response phenotypes.ResultsCOMT/Val158Met and DRD3/Ser9Gly were associated with the responder group (P<0.05). The single-nucleotide polymorphism A-241G of DRD2 gene was related with the resistant-to-treatment group (P<0.001). Finally, Met/Met of COMT and Ser/Gly of DRD3 genes showed a predictive effect associated with the resistant-to-treatment phenotype.ConclusionFurther analyses should be performed to validate these genetic markers as mediators for the response to APs.

show abstract

Section: Discussionmentioning

confidence: 99%

Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

Escamilla¹,

Camarena²,

Saracco-Álvarez³

et al. 2018

NDT

View full text Add to dashboard Cite

show abstract

“…An association was also detected between rs9606186 in COMT and the efficiency of risperidone in a Chinese population (Fijal et al, 2009). Furthermore, the Met allele was associated with improvement in negative symptoms after treatment with risperidone (Kang et al, 2010). This allele is slower than the Val allele in inactivating prefrontal dopamine (Strous et al, 2006), a mechanism potentially involved in modulating the treatment of negative symptoms in schizophrenia (Carlsson, 2006); therefore, Met/Met carriers may benefit enormously from treatment with atypical antipsychotics.…”

Section: Discussionmentioning

confidence: 99%

Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers

Cabaleiro

Ochoa

López‐Rodríguez

et al. 2014

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Contradictive results are also presented by two different groups of rese-archers. A study of Japanese patients declines the correlation between risperiodne and COMT [123], but the recent study of Chinese Han patients confirms the association of risperidone treatment with V108M COMT variant [124]. Met allele is also associated with better cognitive improvement in patients treated with clozapine, as well as with the overall schizophrenia symptoms improvement in olanzapine treated patients [16].…”

Section: Comtmentioning

confidence: 99%

Pharmacogenetics and Antipsychotic Treatment Response/ Фармакогенетски Тестирања И Одговор Кон Третман Со Антипсихотоци

Naumovska

Nesterovska

Filipce

et al. 2015

Prilozi

View full text Add to dashboard Cite

Antipsychotic drugs are widely used in the treatment of schizophrenia and psychotic disorder. The lack of antipsychotic response and treatment-induced side-effects, such as neuroleptic syndrome, polydipsia, metabolic syndrome, weight gain, extrapyramidal symptoms, tardive dyskinesia or prolactin increase, are the two main reasons for non-compliance and increased morbidity in schizophrenic patients. During the past decades intensive research has been done in order to determine the influence of genetic variations on antipsychotics dosage, treatment efficacy and safety. The present work reviews the molecular basis of treatment response of schizophrenia. It highlights the most important findings about the impact of functional polymorphisms in genes coding the CYP450 metabolizing enzymes, ABCB1 transporter gene, dopaminergic and serotonergic drug targets (DRD2, DRD3, DRD4, 5-HT1, 5HT-2A, 5HT-2C, 5HT6) as well as genes responsible for metabolism of neurotransmitters and G signalling pathways (5-HTTLPR, BDNF, COMT, RGS4) and points their role as potential biomarkers in everyday clinical practice. Pharmacogenetic testing has predictive power in the selection of antipsychotic drugs and doses tailored according to the patient’s genetic profile. In this perception pharmacogenetics could help in the improvement of treatment response by using different medicinal approaches that would avoid potential adverse effects, reduce stabilization time and will advance the prognosis of schizophrenic patients.

show abstract

Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia

Cited by 14 publications

References 18 publications

Association study between <em>COMT</em>, <em>DRD2</em>, and <em>DRD3</em> gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

Association study between <em>COMT</em>, <em>DRD2</em>, and <em>DRD3</em> gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers

Pharmacogenetics and Antipsychotic Treatment Response/ Фармакогенетски Тестирања И Одговор Кон Третман Со Антипсихотоци

Contact Info

Product

Resources

About